MorphoSys has filed a patent for the use of a compound called 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, and its salts, in the treatment of thrombocythemia. The patent claims a method of treating essential thrombocythemia (ET) by administering this compound to patients in need. GlobalData’s report on MorphoSys gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights MorphoSys AG - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on MorphoSys, Personalized cancer vaccines was a key innovation area identified from patents. MorphoSys's grant share as of September 2023 was 42%. Grant share is based on the ratio of number of grants to total number of patents.

The patent is filed for a method of treating thrombocythemia

Source: United States Patent and Trademark Office (USPTO). Credit: MorphoSys AG

A recently filed patent (Publication Number: US20230302010A1) describes a method for treating essential thrombocythemia (ET) in patients. The method involves administering a specific compound, 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, or a pharmaceutically acceptable salt of the compound, to patients in need of treatment for ET.

ET is a condition characterized by a high platelet count and abnormal bone marrow biopsy results. The patent claims specify that the patients must have a platelet count equal to or greater than 450×109/L and show specific characteristics in their bone marrow biopsy, such as increased numbers of enlarged, mature megakaryocytes with hyperlobulated nuclei. Additionally, the patients must not meet the criteria for other myeloid neoplasms.

The patent claims also mention that the patients may have other clonal markers or no identifiable cause of thrombocytosis. The clonal markers listed include ASXL1, EZH2, TET2, IDH1/IDH2, SRSF2, or SR3B1 mutations. The cause of thrombocytosis may be related to factors such as infection, inflammation, iron deficiency, or anemia.

The method described in the patent is applicable to high-risk ET patients, particularly those who are 60 years or older and have experienced thrombosis, hemorrhage related to ET, and have diabetes or hypertension requiring pharmacological therapy for more than 60 months. The method may also be used for patients with other specific conditions, such as transient ischemic attack (TIA), erythromelalgia, or severe, recurrent migraines.

The patent claims also mention that the method can be used for patients who have previously been treated with hydroxyurea, but are resistant or intolerant to it. Patients who are anemic, have an enlarged spleen or liver, or are neutropenic (with an absolute neutrophil count less than 1000 neutrophils/µL of blood) may also benefit from this method.

The recommended dosage of the compound is between 100 mg/day to 300 mg/day, and it can be administered as a monohydrate or in crystalline Form A monohydrate.

Overall, this patent describes a method for treating essential thrombocythemia using a specific compound. The method is applicable to patients with specific characteristics and conditions, providing a potential new treatment option for this condition.

To know more about GlobalData’s detailed insights on MorphoSys, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies